In this study, we investigated the predictive value of HER2 mRNA levels in HER2-positive BC patients treated with adjuvant trastuzumab according to ER tumor positivity, and analyzed molecular pathways correlated with HER2 mRNA. This evidence concerns the gene ERBB2 and breast cancer.